—Early-Stage Research Pillar Anticipated to Generate at Least Six Investigational New Drug (IND) Applications by End of 2025— —Company Reveals Select Initial Disease Targets for Next-Generation Gene Therapies and Deimmunized Therapeutic Proteins, Including Duchenne Muscular Dystrophy…
Month: May 2023
Reports first quarter net income of $270.8 million, or $17.01 per diluted share Posts Adjusted EBITDA of $354.4 million for the quarter Continues executing on robust buyback program by returning approximately $200 million to shareholders year-to-date as of May 4, 2023, with roughly $485…
Akebia to host conference call on May 8 at 8:30 a.m. ET Announced vadadustat is now approved in 32 countries following European Commission marketing authorization Expects a response to Formal Dispute Resolution from FDA within next 30 days Released positive top-line results from…
Sequential quarterly meter and RCE growth of 27% and 34%, respectively NEWARK, N.J., May 8, 2023 /PRNewswire/ — Genie Energy, Ltd. (NYSE: GNE, GNEPRA), a leading retail energy and renewable energy solutions provider, today announced results for its first quarter ended March 31, 2023….
CORAL GABLES, Fla., May 8, 2023 /PRNewswire/ — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2023 after…
DUBLIN, May 8, 2023 /PRNewswire/ — Endo International plc (OTC: ENDPQ) today reported financial results for the first-quarter ended March 31, 2023. FIRST-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended March 31, 2023 2022 Change Total Revenues,…
WILMINGTON, Mass., May 8, 2023 /PRNewswire/ – Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (TSXV: SCAN) (OTCQB: LDDFF) (FRANKFURT: LD2A), a leading technology provider of Artificial Intelligence (AI)-based next generation detection solutions for concealed weapons and…
Presentations to Highlight Company’s Gene Therapies for Cancer and Diabetes AUSTIN, Texas, May 8, 2023 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer…
OTTAWA, Ontario–(BUSINESS WIRE)–Kinaxis® Inc. (TSX: KXS), the authority in driving agility for fast, confident decision-making in an unpredictable world, and Exiger, the SaaS company revolutionizing the way corporations, government agencies and banks manage supply chain risk, announced a strategic partnership to enhance proactive supply chain planning with sub-tier supplier visibility, supplier risk detection, and supply chain health analytics. Exiger will join the Kinaxis Ecosystem as a Solu
NEW YORK, May 8, 2023 /PRNewswire/ — The size of the global anti-plagiarism software market for education sector is estimated to increase by USD 2,608.33 million from 2022 to 2027. The market’s growth momentum will progress at a CAGR of 22.87% during the forecast period. The increase in…